Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Tegmine Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tegmine Therapeutics Announces Collaboration with Alloy Therapeutics to Advance Solid Tumor Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"8VC","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alloy Therapeutics Raises $42 Million Series D Financing to Accelerate Discovery Technology Development Across Biologic Modalities","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Technology","graph2":"Discovery"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Normunity","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alloy Therapeutics and Normunity Sign Multi-Program Antibody Discovery Collaboration in Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alloy Therapeutics Launches Proprietary AntiClastic Antisense Oligonucleotide Platform to Make Potent Genetic Medicines","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Partillion Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Partillion Bioscience Corporation Announces Seed Financing, Expanded Board, and New Partnership with Alloy Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Technology","graph2":"Approved"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alloy Therapeutics Announces Platform License Agreement with Lilly","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Technology","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by Alloy Therapeutics

    Menu

    Alloy Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Alloy Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Alloy Therapeutics Announces Platform License Agreement with Lilly

              Details:

              The license provides Lilly access to the ATX-Gx™ and ATX-CLC™ mouse platforms and broad rights to use the Alloy platforms for antibody drug discovery and development.

              Lead Product(s): Antibody-based Therapy

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Eli Lilly

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement May 21, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Alloy Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Partillion Bioscience Corporation Announces Seed Financing, Expanded Board, and New Partnership with Alloy Therapeutics

              Details:

              Under the partnership, Alloy will enable Partillion's ecosystem of drug discovery partners with access to the best expertise and technologies for discovering therapeutic antibodies.

              Lead Product(s): Undisclosed

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Large molecule

              Recipient: Partillion Bioscience

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership September 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Alloy Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Alloy Therapeutics Launches Proprietary AntiClastic Antisense Oligonucleotide Platform to Make Potent Genetic Medicines

              Details:

              AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs optimally created spatial conformation nucleic acids that further enhance the drug-like properties of antisense, which is investigated for the treatment of genetic disease.

              Lead Product(s): Undisclosed

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 28, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Alloy Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Alloy Therapeutics and Normunity Sign Multi-Program Antibody Discovery Collaboration in Immuno-Oncology

              Details:

              The collaboration between Alloy and Normunity is leveraging Alloy’s high velocity antibody discovery services offering, Daedamab, which takes a sequencing-first approach to antibody discovery that reduces discovery timelines without sacrificing quality.

              Lead Product(s): Antibody

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Recipient: Normunity

              Deal Size: $65.0 million Upfront Cash: Undisclosed

              Deal Type: Collaboration November 17, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Alloy Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Alloy Therapeutics Raises $42 Million Series D Financing to Accelerate Discovery Technology Development Across Biologic Modalities

              Details:

              Alloy will use proceeds from the Series D financing to further support the drug discovery community with new pre-competitive drug discovery technologies in new biologic modalities and new partnership models designed to fuel innovation.

              Lead Product(s): In-vivo Human Antibody

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: 8VC

              Deal Size: $42.0 million Upfront Cash: Undisclosed

              Deal Type: Series D Financing October 03, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Alloy Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tegmine Therapeutics Announces Collaboration with Alloy Therapeutics to Advance Solid Tumor Treatment

              Details:

              Tegmine’s discovery capabilities include CRISPR-engineered TegMiner Cells which recapitulate cancer-associated aberrant glycosylation and custom mass spectrometry workflows to identify proteins and PTM-epitopes expressed in primary tumor tissues.

              Lead Product(s): Antibody-based Therapeutic

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Tegmine Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY